McLeod Health issued the following announcement on January 8.
As COVID-19 cases continue to rise due to the Omicron variant, many effective treatment options are in limited supply.
Of the three monoclonal antibody infusion medications available, Sotrovimab is the only one showing effectiveness against Omicron. However, the federal government’s current supply of Sotrovimab is extremely limited which is directly impacting availability across the state.
McLeod Health is monitoring the supply of monoclonal antibody therapeutics and prioritizing patients to ensure that individuals at highest risk for developing severe COVID-19 receive the treatment. Those at highest risk include: individuals ages 65 years and older, pregnant women, and highly immunocompromised patients.
Monoclonal antibody infusion treatment will only be available at McLeod Regional Medical Center and McLeod Health Seacoast until supply issues are resolved.
At this time, patients must be referred by a physician for this treatment. McLeod Health will accommodate as many referrals as possible.
At McLeod Health, we encourage everyone to do their part to stop the spread of COVID-19 by getting vaccinated, receiving the booster when you are eligible, wearing masks, social distancing and washing their hands. We want to keep our community healthy and our staff safe in their calling to care for others.
Original source can be found here.
Alerts Sign-up